Goodrx Holdings Inc
NASDAQ:GDRX
Goodrx Holdings Inc
Cost of Revenue
Goodrx Holdings Inc
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Goodrx Holdings Inc
NASDAQ:GDRX
|
Cost of Revenue
-$66.9m
|
CAGR 3-Years
-31%
|
CAGR 5-Years
-62%
|
CAGR 10-Years
N/A
|
|
Veeva Systems Inc
NYSE:VEEV
|
Cost of Revenue
-$677.3m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
-23%
|
|
Inspire Medical Systems Inc
NYSE:INSP
|
Cost of Revenue
-$96.6m
|
CAGR 3-Years
-76%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
Evolent Health Inc
NYSE:EVH
|
Cost of Revenue
-$1.5B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
Doximity Inc
NYSE:DOCS
|
Cost of Revenue
-$53.5m
|
CAGR 3-Years
-53%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Certara Inc
NASDAQ:CERT
|
Cost of Revenue
-$141m
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
See Also
What is Goodrx Holdings Inc's Cost of Revenue?
Cost of Revenue
-66.9m
USD
Based on the financial report for Dec 31, 2023, Goodrx Holdings Inc's Cost of Revenue amounts to -66.9m USD.
What is Goodrx Holdings Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-62%
Over the last year, the Cost of Revenue growth was -3%. The average annual Cost of Revenue growth rates for Goodrx Holdings Inc have been -31% over the past three years , -62% over the past five years .